TuHURA Biosciences Inc (HURA) Key Metrics
HURA valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $112.2M
- Enterprise value
- $139.1M
- P/E (TTM)
- —
- Forward P/E
- —
- PEG ratio
- —
- Price / sales
- —
- Price / book
- 7.2
- EV / EBITDA
- —
- Dividend yield
- —
- Beta
- —
HURA key metrics, FY2017–FY2026
Fiscal year ended June 30, 2026 · U.S. dollarsHURA valuation Price multiples at each fiscal year-end price.
HURA returns How much profit the business earns on the capital it uses.
HURA per-share figures Results divided by the shares outstanding at year-end.
HURA financial health Debt, liquidity and how easily interest is covered.
HURA valuation history
HURA returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
HURA debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
HURA cash returned to shareholders
HURA price vs earnings per share
HURA key metrics
FY2017–FY2026| FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Valuation | ||||||||||
| Market capitalization | $112.1M | $41.6M | — | — | — | — | — | — | — | — |
| Enterprise value | $109.2M | $29.2M | — | — | — | — | — | — | — | — |
| Price / book | 5.4 | 2.9 | — | — | — | — | — | — | — | — |
| Earnings yield | −26.8% | −52.1% | — | — | — | — | — | — | — | — |
| Free cash flow yield | −24.7% | −35.5% | — | — | — | — | — | — | — | — |
| Dividend yield | 0.0% | 0.0% | — | — | — | — | — | — | — | — |
| Shareholder yield (dividends + buybacks) | 0.0% | 0.0% | — | — | — | — | — | — | — | — |
| Share price at fiscal year-end | $2.34 | $2.23 | $9.45 | $141.05 | $486.50 | $3,972.50 | $1,204.00 | $2,257.50 | $11,952.50 | $40,075.00 |
| Per share | ||||||||||
| Revenue per share | $0.00 | $0.00 | — | — | — | — | — | — | — | — |
| Earnings per share | −$0.63 | −$1.16 | — | — | — | — | — | — | — | — |
| Operating cash flow per share | −$0.58 | −$0.79 | — | — | — | — | — | — | — | — |
| Free cash flow per share | −$0.58 | −$0.79 | — | — | — | — | — | — | — | — |
| Cash per share | $0.08 | $0.68 | — | — | — | — | — | — | — | — |
| Book value per share | $0.44 | $0.78 | — | — | — | — | — | — | — | — |
| Tangible book value per share | −$0.02 | $0.78 | — | — | — | — | — | — | — | — |
| Dividends per share | $0.00 | $0.00 | — | — | — | — | — | — | — | — |
| Capex per share | $0.00 | $0.00 | — | — | — | — | — | — | — | — |
| Debt per share | $0.01 | $0.01 | — | — | — | — | — | — | — | — |
| Shares outstanding | 47.9M | 18.7M | — | — | — | — | — | — | — | — |
| Change in shares outstanding | +156.8% | — | — | — | — | — | — | — | — | — |
| Returns & profitability | ||||||||||
| Return on equity (ROE) | −169.2% | −332.7% | — | −253.5% | — | −706.3% | −818.3% | −217.4% | −185.4% | −141.3% |
| Return on invested capital (ROIC) | −249.3% | — | — | — | — | — | — | — | — | — |
| Return on assets (ROA) | −127.1% | −178.2% | −85.1% | −135.6% | −227.2% | −464.8% | −261.7% | −144.9% | −148.7% | −113.3% |
| Return on tangible assets | −562.9% | −108.6% | −190.7% | −96.4% | −354.0% | −282.8% | −310.6% | −199.9% | −158.1% | −102.7% |
| Financial health | ||||||||||
| Total debt | $700,022 | $202,542 | $2.3M | $138,224 | $644,070 | — | — | — | — | — |
| Cash & short-term investments | $3.6M | $12.7M | $3.7M | $14.3M | $5.5M | $10.5M | $2.4M | $3.7M | $6.0M | $6.6M |
| Net debt | −$2.9M | −$12.5M | −$1.3M | −$14.1M | −$4.9M | −$10.5M | −$2.4M | −$3.7M | −$6.0M | −$6.6M |
| Debt / equity | 0.03 | 0.01 | — | 0.01 | — | — | — | — | — | — |
| Debt / assets | 0.03 | 0.01 | 0.54 | 0.01 | 0.10 | — | — | — | — | — |
| Current ratio | 0.78 | 3.68 | 1.16 | 5.13 | 0.79 | 4.24 | 1.03 | 1.94 | 4.30 | 6.03 |
| Quick ratio | 0.78 | 3.64 | 1.16 | 5.13 | 0.79 | 4.24 | 1.03 | 1.94 | 4.30 | 6.03 |
| Interest coverage | -50.9 | -4.3 | -452.2 | — | -36.0 | -179.8 | — | — | — | — |
| Working capital | −$1.3M | $14.3M | $562,422 | $11.9M | −$1.5M | $9.0M | $82,000 | $2.0M | $5.4M | $6.6M |
| Invested capital | $18.0M | $2.1M | −$2.9M | −$1.8M | −$5.6M | $44,000 | −$2.1M | −$1.8M | −$536,772 | −$7,490 |
| Tangible asset value | −$1.1M | $14.6M | −$1.6M | $12.3M | −$747,821 | $10.6M | $263,000 | $2.0M | $5.4M | $6.5M |
| Net current asset value | −$1.8M | $14.2M | −$1.8M | $11.9M | −$1.5M | $8.8M | $82,000 | $2.0M | $5.4M | $6.5M |
| Graham net-net per share | −$0.06 | $0.41 | — | — | — | — | — | — | — | — |
| Capital allocation | ||||||||||
| Dividends paid | $8,356 | $0 | $6,000 | $8,000 | $8,000 | $8,000 | $8,000 | $8,356 | $8,356 | $8,356 |
| Share buybacks (net) | — | $0 | $24,751 | $0 | — | — | — | — | — | — |
| Capex / depreciation | 1.07 | 0.50 | 0.45 | 0.10 | 0.01 | 0.25 | 0.00 | 0.00 | 401.62 | 0.00 |
| Efficiency | ||||||||||
| Days of inventory on hand | — | 671.5 | — | — | — | — | — | — | — | — |
| Days payables outstanding | — | 7,849.1 | 12,551.1 | 7,085.7 | 8,008.1 | 24,124.2 | 68,538.2 | 35,975.4 | 20,456.5 | 20,770.6 |
| Receivables turnover | — | 0.00 | 0.00 | 0.00 | — | — | — | 0.00 | 0.00 | 0.00 |
| Payables turnover | — | 0.05 | 0.03 | 0.05 | 0.05 | 0.02 | 0.01 | 0.01 | 0.02 | 0.02 |
| Inventory turnover | — | 0.54 | — | — | — | — | — | — | — | — |
| Asset turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average receivables | — | $278,572 | $217,934 | $101,424 | — | — | — | $32,853 | $58,057 | $47,491 |
| Average payables | $3.5M | $2.5M | $1.9M | $1.2M | $1.3M | $2.1M | $1.9M | $1.6M | $1.4M | $949,358 |
| Average inventory | — | $214,699 | — | — | — | — | — | — | — | — |
| Intangibles / total assets | 80.5% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.3% | 0.4% | 0.5% |
Computed from HURA's annual financial statements (latest annual report filed March 31, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
HURA valuation and financial ratios
TuHURA Biosciences earned a return on equity of −169.2% and a return on invested capital of −249.3% in fiscal 2026. It ended the year with $0.7 million of debt and $3.6 million in cash and short-term investments, a net cash position of $2.9 million. It returned $0.0 million to shareholders: $0.0 million in dividends and $0 in share buybacks.
See the HURA income statement, the HURA chart for price history, or the HURA stock overview for the latest quote and news.
HURA key metrics FAQ
What is TuHURA Biosciences's return on equity?
TuHURA Biosciences's return on equity (ROE) was −169.2% in fiscal 2026: net income of -$30.1 million on average shareholders' equity of $17.8 million.
What is TuHURA Biosciences's ROIC?
TuHURA Biosciences's return on invested capital was −249.3% in fiscal 2026, using after-tax operating income divided by average debt plus equity minus cash.
How much debt does TuHURA Biosciences have?
TuHURA Biosciences had total debt of $0.7 million at the end of fiscal 2026, a debt-to-equity ratio of 0.03 and more cash than debt.
What is TuHURA Biosciences's dividend yield?
TuHURA Biosciences paid $0.0 million in dividends in fiscal 2026 ($0.00 per share), a payout ratio of —.
What is TuHURA Biosciences's free cash flow yield?
TuHURA Biosciences generated -$27.7 million of free cash flow in fiscal 2026, a free cash flow yield of −24.7% on its market value at year-end ($112.1 million).
What is TuHURA Biosciences's current ratio?
TuHURA Biosciences's current ratio was 0.78 at the end of fiscal 2026: current assets were 0.78 times current liabilities.